Michael Grissinger appointed as new Chairman of AnaCardio

Stockholm, Sweden, June 3, 2024  AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board. Michael has had a long and successful career in the pharmaceutical industry, leading large value business  development transactions […]